Treatment Of Chronic Hcv With Direct Acting Antivirals
Download Treatment Of Chronic Hcv With Direct Acting Antivirals full books in PDF, epub, and Kindle. Read online free Treatment Of Chronic Hcv With Direct Acting Antivirals ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Mitchell L. Shiffman |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 333 |
| Release | : 2011-11-17 |
| Genre | : Medical |
| ISBN | : 1461411920 |
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 297 |
| Release | : 2017-07-30 |
| Genre | : Medical |
| ISBN | : 0309457297 |
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 187 |
| Release | : 2016-06-01 |
| Genre | : Medical |
| ISBN | : 0309438020 |
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
| Author | : Irwin M. Arias |
| Publisher | : John Wiley & Sons |
| Total Pages | : 1156 |
| Release | : 2020-03-09 |
| Genre | : Medical |
| ISBN | : 1119436826 |
Bridging the gap between basic scientific advances and the understanding of liver disease — the extensively revised new edition of the premier text in the field. The latest edition of The Liver: Biology and Pathobiology remains a definitive volume in the field of hepatology, relating advances in biomedical sciences and engineering to understanding of liver structure, function, and disease pathology and treatment. Contributions from leading researchers examine the cell biology of the liver, the pathobiology of liver disease, the liver’s growth, regeneration, metabolic functions, and more. Now in its sixth edition, this classic text has been exhaustively revised to reflect new discoveries in biology and their influence on diagnosing, managing, and preventing liver disease. Seventy new chapters — including substantial original sections on liver cancer and groundbreaking advances that will have significant impact on hepatology — provide comprehensive, fully up-to-date coverage of both the current state and future direction of hepatology. Topics include liver RNA structure and function, gene editing, single-cell and single-molecule genomic analyses, the molecular biology of hepatitis, drug interactions and engineered drug design, and liver disease mechanisms and therapies. Edited by globally-recognized experts in the field, this authoritative volume: Relates molecular physiology to understanding disease pathology and treatment Links the science and pathology of the liver to practical clinical applications Features 16 new “Horizons” chapters that explore new and emerging science and technology Includes plentiful full-color illustrations and figures The Liver: Biology and Pathobiology, Sixth Edition is an indispensable resource for practicing and trainee hepatologists, gastroenterologists, hepatobiliary and liver transplant surgeons, and researchers and scientists in areas including hepatology, cell and molecular biology, virology, and drug metabolism.
| Author | : World Health Organization |
| Publisher | : World Health Organization |
| Total Pages | : 0 |
| Release | : 2017 |
| Genre | : Medical |
| ISBN | : 9789241549981 |
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
| Author | : Barry W. Hancock |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 228 |
| Release | : 1982-12-31 |
| Genre | : Medical |
| ISBN | : 9789024727124 |
The assessment of tumour response after treatment is one of the most important challenges in Oncology and the picture is so often complicated by the effects of therapy itself. Clinical assessment is still by far the most important method of assessment at our disposal but there is increasing dependence on investigations of all types as indices of response. This depenƯ dence may be misplaced if inappropriate investigations are pursued and we have tried to emphasise in this book the importance of selectivity. Some indices of assessment (e. g. tumour markers, organ imaging) have a vital role to play; others (e. g. histopathology, genetics) are assuming greater imporƯ tance as tumour behaviour becomes better understood. One subject, ImmuƯ nology, is still in its infancy as regards tumour follow-up, but shows much promise so that a full account of tumour immunology and trends in immuƯ notherapy has been included. I am grateful to Dr. Brian Ross for his help with the chapter on Organ Imaging, to the Department of Medical Illustration for their ever-ready co-operation with illustrations and photographs and to Miss Shirley Francis for doing much of the typing. B.W. HANCOCK List of Contributors HANCOCK, B.W., MD, DCH, MRCP, Senior Lecturer in Medicine, HonƯ orary Consultant Physician, Royal Hallamshire & Weston Park Hospitals, Sheffield, U.K. NEAL, F.E., KSG, MBChB, FRCR, DMRT, Consultant Radiotherapist & Oncologist, Weston Park Hospital, Sheffield, u. K. POTTER, AM.
| Author | : Angelos Hatzakis |
| Publisher | : Springer Nature |
| Total Pages | : 219 |
| Release | : 2021-05-10 |
| Genre | : Medical |
| ISBN | : 3030677621 |
This volume provides the reader with a detailed overview of the current state-of-the art approach of Hepatitis C management. It reviews the course of action in handling of chronic Hepatitis C patients with various HCV genotypes and treats special cases such as acute hepatitis, transplant and renal patients as well as people who inject drugs. The two volume work on Hepatitis C introduces to the topic by reviewing virology, diagnosis, epidemiology, prevention, management and elimination of HCV. The book provides a valuable source at full length for researchers and clinicians working on Hepatitis C.
| Author | : D. J. Jeffries |
| Publisher | : |
| Total Pages | : 614 |
| Release | : 1995-07-11 |
| Genre | : Medical |
| ISBN | : |
Considerable advances have been made in the treatment of antiviral diseases over the last decade. Several new drugs have been introduced while new clinical information has been gathered on the efficacy of existing drugs. This study aims to provide an examination of the basic science (drug formulae, structure and biochemical activity) and clinical information (usage and efficacy) on chemotherapy, as well as describing future potentials.
| Author | : Kazuaki Chayama |
| Publisher | : Springer |
| Total Pages | : 80 |
| Release | : 2016-11-01 |
| Genre | : Medical |
| ISBN | : 9811024162 |
This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.
| Author | : Imran Shahid |
| Publisher | : Bentham Science Publishers |
| Total Pages | : 450 |
| Release | : 2023-01-24 |
| Genre | : Medical |
| ISBN | : 9815123440 |
The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease’s progression along with extrahepatic manifestations and virus invasion strategies impacting the host’s immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management. Topics covered in the chapters include 1) HCV-host interactions leading to asymptomatic acute infection, 2) the progression of acute HCV infection to chronic disease and subsequent extrahepatic comorbidities, 3) Innate and adaptive immune responses in HCV infections, 4) Consensus-based Approaches for Hepatitis C Screening and Diagnosis, 5) advances in hepatitis C therapy and global management of HCV, and 6) the outcomes of Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. This book is a valuable addition to undergraduate and postgraduate hepatology students and physicians, clinicians, hepatologists, and health care officials involved in HCV clinical diagnosis and therapeutics.
